Positive Phase III data will support supplemental FDA application for Eylea

Regeneron Pharmaceuticals (Nasdaq: REGN) has released positive data from the Phase III PANORAMA trial evaluating Eylea (aflibercept) in certain diabetic retinopathy patients.

The trial met its 24-week primary endpoint, with 58% of the test group experiencing a two-step or greater improvement from baseline according to a commonly-used measure. This compares with 6% for the sham group.

Regeneron, which has invested in further clinical trials including one to test a new quarterly dosing regimen, is in competition with Novartis (NOVN: VX) and Roche (ROG: SIX), who are testing rival candidates brolucizumab and RG7716, respectively.